Phase
Condition
Stomach Cancer
Digestive System Neoplasms
Gastric Ulcers
Treatment
True electroacupuncture + True self-administered acupressure
Sham electroacupuncture + Sham self-administered acupressure
Doctor-prescribed treatment
Clinical Study ID
Ages 18-85 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Sign a written informed consent form;
Male or female ≥ 18 years old;
Patients with gastrointestinal cancer or breast cancer who are diagnosed with cancerby pathology will receive capecitabine treatment for the first time according to thelabel;
The performance status of the Eastern Cancer Collaboration Group is 0-2;
Palliative or adjuvant chemotherapy with capecitabine (combination or monotherapy,minimum daily total dose of capecitabine 2000 mg/m^2);
Expected lifespan ≥ 3 months;
Laboratory requirements: platelet count ≥ 100 × 10^9/L, white blood cellcount>3.0 × 10^9/L, hemoglobin ≥ 10.0 g/dL, normal liver and kidneyfunction;
Adequate contraception.
Exclusion
Exclusion Criteria:
Previous use of capecitabine or liposome doxorubicin or any other tyrosine kinaseinhibitor that may induce HFS (such as sorafenib, sunitinib, and apatinib) forchemotherapy;
The initial dose of capecitabine is less than 800mg/m^2;
Radiation therapy or surgery should be performed within 4 weeks before the start oftreatment;
Skin diseases that may interfere with clinical trial results;
Known drug/alcohol abuse;
Pregnant women or lactating patients;
Participate in another clinical trial and the patient has received theinvestigational drug within the last 30 days prior to the start of treatment (i.e.follow-up in the previous trial was not exclusive);
Known patients who are afraid of electroacupuncture stimulation or allergic tostainless steel needles or any component of capecitabine;
Receive any acupuncture and moxibustion treatment ,there is lymphedema in the areastimulated by acupuncture;
Patients with any chemotherapy- or radiotherapy-related toxicities that have notsubsided to grade 2 or lower will be excluded, except for stable sensory neuropathy.
Any unresolved skin toxicity caused by previous chemotherapy or radiotherapy, exceptfor hair loss, will also be grounds for exclusion.
Study Design
Study Description
Connect with a study center
Qinghai University Affiliated Hospital
Xining, Qinghai 810000
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.